Compare Abbott Laboratories (ABT) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Tyson Foods, Inc. — how do they compare? Abbott Laboratories trades at $95.31 (market cap $166.94B), while Tyson Foods, Inc. trades at $58.66 (market cap $20.71B). The key difference: Abbott Laboratories is far larger — about 8.1× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| ABT | TSN | |
|---|---|---|
Market Cap | $166.94B | $20.71B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $68.75 |
52-Week Low | $82.57 | $50.72 |
Enterprise Value | $193.69B | $28.30B |
Dividend Yield | 2.63% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Tyson Foods (TSN) trades at $58.82, down 0.12% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Revenue for 2025 was $54.44 billion, with a net income margin of 0.81%. Recent news highlights innovation in prepared foods and new product launches, while analyst consensus is a Buy with a $69.75 price target.
The outlook for TSN is cautiously optimistic, supported by analyst bullishness and strategic growth in value-added products. Key opportunities include strong free cash flow guidance and debt reduction. Risks involve volatile cattle prices, inflationary pressures, and competitive market dynamics. The stock presents a potential upside from current levels, contingent on execution of long-term growth strategies and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
